Latest & greatest articles for hydrochlorothiazide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hydrochlorothiazide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hydrochlorothiazide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hydrochlorothiazide

41. Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion. (PubMed)

Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion. 14 hypertensive men with type II diabetes sequentially received, in random order, hydrochlorothiazide 50 mg twice a day, propranolol 80 mg twice a day, and both drugs in combination. The 3-week treatment periods were separated by a 1-week washout period. Hydrochlorothiazide significantly increased fasting glucose by 31% (p less than 0.05) and glycosylated (...) haemoglobin (HbA1c) by 6.0% (p less than 0.10). A similar treatment period of propranolol 80 mg twice a day caused no significant increases. However, when both drugs were taken in combination, fasting glucose rose by 56% and HbA1c by 14.7% (p less than 0.01). The hyperglycaemic effect of hydrochlorothiazide and its potentiation by propranolol were independent of serum potassium and of endogenous insulin secretion as measured by urine C-peptide excretion. The combination of hydrochlorothiazide

1985 Lancet

42. Cardiovascular effects of acebutolol and hydrochlorothiazide in essential hypertension. (PubMed)

Cardiovascular effects of acebutolol and hydrochlorothiazide in essential hypertension. 7040230 1982 06 21 2016 07 26 0194-911X 4 2 1982 Mar-Apr Hypertension (Dallas, Tex. : 1979) Hypertension Cardiovascular effects of acebutolol and hydrochlorothiazide in essential hypertension. 320-4 Ogilvie R I RI Nadeau J H JH eng Clinical Trial Comparative Study Controlled Clinical Trial Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't United States Hypertension 7906255 0194 (...) -911X 0J48LPH2TH Hydrochlorothiazide 67P356D8GH Acebutolol IM Acebutolol therapeutic use Aged Blood Pressure drug effects Clinical Trials as Topic Double-Blind Method Female Forearm blood supply Heart Rate drug effects Hemodynamics drug effects Humans Hydrochlorothiazide therapeutic use Hypertension drug therapy Male Middle Aged Vascular Resistance drug effects 1982 3 1 1982 3 1 0 1 1982 3 1 0 0 ppublish 7040230

1982 Hypertension (Dallas, Tex. : 1979)

43. Comparison of propranolol and hydrochlorothiazide for thr initial treatment of hypertension. I. Results of short-term titration with emphasis on racial differences in response. Veterans Administration Cooperative Study Group on Antihypertensive agents. (PubMed)

Comparison of propranolol and hydrochlorothiazide for thr initial treatment of hypertension. I. Results of short-term titration with emphasis on racial differences in response. Veterans Administration Cooperative Study Group on Antihypertensive agents. We compared hydrochlorothiazide and propranolol hydrochloride for monotherapy of hypertension by a double-blind study of 683 men who were titrated to less than 90 mm Hg diastolic BP or to 640 mg of propranolol or 200 mg of hydrochlorothiazide (...) . Propranolol reduced systolic BP from 146.0 +/- 14.4 (SD) to 134.8 +/- 16.3 mm Hg and diastolic BP from 101.6 +/- 4.6 to 90.5 +/- 7.5 mm Hg. Hydrochlorothiazide lowered both systolic BP more effectively from 146.5 +/- 15.8 to 128.8 +/- 12.2 mm Hg and diastolic BP from 101.3 +/- 4.5 to 89.4 +/- 6.5 mm Hg. In blacks, hydrochlorothiazide lowered systolic BP 20.3 +/- 14.3 mm Hg v 8.2 +/- 12.2 mm Hg for propranolol; hydrochlorothiazide reduced diastolic BP 13.0 +/- 7.0 mm Hg v 9.5 +/- 7.0 for propranolol

1982 JAMA

44. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy. Veterans Administration Cooperative Study Group on Antihypertensive Agents. (PubMed)

Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy. Veterans Administration Cooperative Study Group on Antihypertensive Agents. As described in the preceding communication, either propranolol hydrochloride or hydrochlorothiazide were randomly allocated in a double-blind manner to 683 patients with initial diastolic BP in the range of 95 to 114 mm Hg. Of this number, 394 entered the long-term treatment phase. During (...) the subsequent 12 months of long-term treatment, hydrochlorothiazide was more effective than propranolol in controlling BP (mean reductions, -17.5/-13.1 mm Hg with hydrochlorothiazide compared with -8.3/-11.3 with propranolol. After treatment with hydrochlorothiazide, a greater percentage of patients achieved the goal diastolic BP of less than 90 mm Hg (65.5% compared with 52.8% taking propranolol). Also during treatment, fewer patients receiving hydrochlorothiazide required termination as compared

1982 JAMA

45. Comparative effects of ticrynafen and hydrochlorothiazide in the treatment of hypertension. (PubMed)

Comparative effects of ticrynafen and hydrochlorothiazide in the treatment of hypertension. Two dose levels of ticrynafen, a new uricosuric diuretic, and of hydrochlorothiazide were randomly assigned, double-blind to 240 men with initial diastolic blood pressures in the range of 95 to 114 mm Hg. A dose of 500 mg of ticrynafen once daily exerted an antihypertensive effect comparable to that of 50 or 100 mg of hydrochlorothiazide. Whereas serum uric acid levels rose in patients treated (...) with hydrochlorothiazide, they fell markedly in those receiving ticrynafen. Otherwise, both diuretics produced similar chemical changes in serum. Patients tolerated ticrynafen as well as they did hydrochlorothiazide over a period of six months of observation, and there was no evidence of serious toxicity or loss of therapeutic effect with ticrynafen. This antihypertensive agent, in appropriate doses, appears to be as effective and well tolerated as hydrochlorothiazide, and in addition ticrynafen prevents hyperuricemia.

1979 NEJM

46. Ticrynafen and hydrochlorothiazide. A double-blind study of antihypertensive properties with an open crossover. (PubMed)

Ticrynafen and hydrochlorothiazide. A double-blind study of antihypertensive properties with an open crossover. Twenty-eight patients completed a double-blind study of the antihypertensive effects of ticrynafen compared with those of hydrochlorothiazide. The results of blood pressure reduction were comparable in the two groups. After six months, 12 patients were crossed over to ticrynafen therapy from hydrochlorothiazide. They maintained their blood pressure reduction. The most striking (...) difference between the two groups was in the uric acid response. The uric acid level in the patients receiving hydrochlorothiazide therapy rose from a baseline of 5.9 to 7.5 mg/dL (normal range, 3.0 to 8.0 mg/dL). The uric acid level of those patients receiving ticrynafen therapy decreased from a baseline of 6.4 mg/dL to a low of 3.3 mg/dL. In view of ticrynafen's appreciable antihypertensive and uric-acid-lowering effects, it appears to be a useful new antihypertensive drug.

1979 JAMA

47. Furosemide compared with hydrochlorothiazide. Long-term treatment of hypertension. (PubMed)

Furosemide compared with hydrochlorothiazide. Long-term treatment of hypertension. In a double-blind crossover study, the effectiveness of furosemide, 40 mg twice daily, was compared with hydrochlorothiazide, 50 mg twice daily, in hypertensive patients. Both hydrochlorothiazide and furosemide significantly reduced blood pressure (BP) during three months of therapy. However, the fall in BP was consistently greater with hydrochlorothiazide than with furosemide, although the difference (...) was significant only with respect to systolic BP. The somewhat greater antihypertensive effectiveness of hydrochlorothiazide may be related to its longer action permitting a more continuous diuretic effect and, hence, maintenance of reduced extracellular fluid volume throughout the 24-hour period.

1978 JAMA

48. [The antihypertensive effect of a new beta-blocking drug timolol in combination with hydrochlorothiazide]. (PubMed)

[The antihypertensive effect of a new beta-blocking drug timolol in combination with hydrochlorothiazide]. 7444 1976 10 01 2013 11 21 0012-7183 92 11 1976 Duodecim; laaketieteellinen aikakauskirja Duodecim [The antihypertensive effect of a new beta-blocking drug timolol in combination with hydrochlorothiazide]. 588-96 Pyörälä K K Mattila S S Leirisalo M M Toivonen S S fin Clinical Trial English Abstract Journal Article Randomized Controlled Trial Timololin ja hydroklortiatsidin yhdistelmän (...) verenpainetta alentava vaikutus Finland Duodecim 0373207 0012-7183 0 Adrenergic beta-Antagonists 0J48LPH2TH Hydrochlorothiazide IM Adrenergic beta-Antagonists therapeutic use Adult Clinical Trials as Topic Drug Evaluation Drug Therapy, Combination Female Humans Hydrochlorothiazide therapeutic use Hypertension drug therapy Male Middle Aged 1976 1 1 1976 1 1 0 1 1976 1 1 0 0 ppublish 7444

1976 Duodecim; laaketieteellinen aikakauskirja

49. Effects of timolol and hydrochlorothiazide on blood-pressure and plasma renin activity. Double-blind factorial trial. (PubMed)

Effects of timolol and hydrochlorothiazide on blood-pressure and plasma renin activity. Double-blind factorial trial. The effects of timolol (10 mg thrice daily) and hydrochlorothiazide (50 mg/day) have been compared in a double-blind factorial trial in 20 patients with essential hypertension. There were four randomised test phases of 8 weeks each during which patients received timolol alone, hydrochlorothiazide alone, timolol plus hydrochlorothiazide, and no treatment (placebo). Blood-pressure (...) was measured weekly, alternately at the outpatient clinic and at the patient's home. Supine mean arterial pressure fell from 119 mm Hg in the placebo phase to 110 mm Hg in the hydrochlorothiazide phase, 106 mm Hg in the timolol phase, and 101 mm Hg in the combined timolol plus hydrochlorothiazide phase. Factorial analysis revealed that these effects of the two drugs were additive without any potentiation or antagonism. Mean plasma-renin activity (P.R.A.) was 5-02 ng/ml/3 h in the placebo phase falling to 1

1976 Lancet

50. Efficacy of an antihypertensive agent. Comparison of methyldopa and hydrochlorothiazide in combination and singly. (PubMed)

Efficacy of an antihypertensive agent. Comparison of methyldopa and hydrochlorothiazide in combination and singly. In a double-blind evaluation, the efficacy of a combination of methyldopa with hydrochlorothiazide was compared with that of its components, methyldopa and hydrochlorothiazide. The combination was found to be more efficacious than either of its components. It reduced the arithmetic mean of the pressures of all patients from 170/116 to 133/95 mm Hg in four weeks. Despite the greater

1975 JAMA

51. Metabolic and hypotensive effects of ethacrynic acid. Comparative study with hydrochlorothiazide. (PubMed)

Metabolic and hypotensive effects of ethacrynic acid. Comparative study with hydrochlorothiazide. 5694972 1968 08 29 2016 10 17 0098-7484 205 1 1968 Jul 01 JAMA JAMA Metabolic and hypotensive effects of ethacrynic acid. Comparative study with hydrochlorothiazide. 81-5 Russell R P RP Lindeman R D RD Prescott L F LF eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial United States JAMA 7501160 0098-7484 0 Blood Glucose 0 Chlorides 0 Placebos 0J48LPH2TH (...) Hydrochlorothiazide 142M471B3J Carbon Dioxide 268B43MJ25 Uric Acid 9NEZ333N27 Sodium EC 2.6.1.1 Aspartate Aminotransferases M5DP350VZV Ethacrynic Acid RWP5GA015D Potassium AIM IM Analysis of Variance Aspartate Aminotransferases blood Blood Glucose analysis Blood Pressure drug effects Blood Urea Nitrogen Body Weight Carbon Dioxide blood Chlorides blood Ethacrynic Acid therapeutic use Female Glucose Tolerance Test Humans Hydrochlorothiazide therapeutic use Hypertension drug therapy metabolism Male Middle Aged

1968 JAMA

52. Prophylactic use of hydrochlorothiazide in pregnancy. (PubMed)

Prophylactic use of hydrochlorothiazide in pregnancy. 5332983 1967 02 10 2016 10 17 0098-7484 198 11 1966 Dec 12 JAMA JAMA Prophylactic use of hydrochlorothiazide in pregnancy. 1150-4 Kraus G W GW Marchese J R JR Yen S S SS eng Clinical Trial Journal Article Randomized Controlled Trial United States JAMA 7501160 0098-7484 0J48LPH2TH Hydrochlorothiazide AIM IM Clinical Trials as Topic Female Humans Hydrochlorothiazide adverse effects therapeutic use Hypertension prevention & control Infant

1967 JAMA